Menu Search
Equities

Achieve Life Sciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SP4P:MUN

Achieve Life Sciences Inc

Actions
  • Price (EUR)3.56
  • Today's Change-0.025 / -0.70%
  • Shares traded35.00
  • 1 Year change+10.40%
  • Beta1.8257
Data delayed at least 15 minutes, as of Feb 13 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

  • Revenue in USD (TTM)0.00
  • Net income in USD-52.35m
  • Incorporated1995
  • Employees25.00
  • Location
    Achieve Life Sciences Inc22722 29TH DR. SE, SUITE 100SEATTLE 98021United StatesUSA
  • Phone+1 (425) 686-1500
  • Fax+1 (302) 636-5454
  • Websitehttps://achievelifesciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.